SBI-425
CAS No. 1451272-71-1
SBI-425 ( —— )
Catalog No. M26818 CAS No. 1451272-71-1
SBI-425 is an effective and orally bioavailable inhibitor of tissue-nonspecific alkaline phosphatase (TNAP).
Purity : >98% (HPLC)
Size | Price / USD | Stock | Quantity |
5MG | 65 | Get Quote |
|
10MG | 107 | Get Quote |
|
25MG | 173 | Get Quote |
|
50MG | 252 | Get Quote |
|
100MG | 374 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSBI-425
-
NoteResearch use only, not for human use.
-
Brief DescriptionSBI-425 is an effective and orally bioavailable inhibitor of tissue-nonspecific alkaline phosphatase (TNAP).
-
DescriptionSBI-425 is an effective and orally bioavailable inhibitor of tissue-nonspecific alkaline phosphatase (TNAP). SBI-425 effectively inhibits TNAP in the vasculature and improves cardiovascular parameters and survival without a detectable change in the bone.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1451272-71-1
-
Formula Weight341.8
-
Molecular FormulaC13H12ClN3O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1ccc(Cl)cc1S(=O)(=O)Nc1cncc(c1)C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
D ALLOSE
D-Allose is a rare naturally occurring monosaccharide known to exert anti-proliferative effects on cancer cells. The effects of D-Allose on the cellular membranes of hormone-refractory prostate cancer cell line (DU145) hormone-sensitive prostate cancer cell line (LNCaP) and normal prostate epithelial cells (PrEC) were studied at the molecular level by phospholipid profiling using a shotgun lipidomic method.
-
Kizuta saponin K11
Kizuta saponin K11 is a saponin derived from Kalopanax pictum var. maximowiczii leaves, which is a widely used Korean medicinal plant.
-
Infree
Infree is a prodrug of indomethacin. It acts as a nonsteroidal anti-inflammatory drug (NSAID) and disease-modifying anti-rheumatic drug (DMARD).